After calling Rockville, Maryland, home for more than eight years, Big Pharma GSK is planning to move its vaccine and ...

Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

Arizona Attorney General Kris Mayes on Thursday sued pharmaceutical manufacturer GlaxoSmithKline for engaging in deceptive and unfair practices ...

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point for ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

EMA has accepted GSK’s application for a prefilled syringe presentation of Shingrix for review. Credit: Vivida Photo PC/Shutterstock. GSK and the University of Oxford have entered a new research ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...